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Summary 
Nitric oxide (NO) regulates both vascular tone and platelet function. Since thrombotic 
diseases and their animal models consist of both vascular and platelet components, the 
functional mechanisms by which NO and endothelial nitric oxide synthase (eNOS) 
regulate thrombotic events are unclear. 
Experiments were conducted by measuring collagen induced aggregation of freely 
circulating radiolabelled platelets in the pulmonary vasculature of anaesthetised mice 
via external detection probes.  In addition, cardiac haemodynamic function was assessed 
by invasive catheterisation during thrombotic stimulation. 
Platelet aggregation responses were shown to occur independently of changes in vessel 
tone induced by pharmacological vasoconstriction or vasodilatation. Acute NOS 
inhibition significantly potentiated the amplitude and duration of platelet aggregation 
and an NO donor had an inhibitory effect. In contrast, in eNOS-/- mice, the amplitude of 
platelet aggregation was not affected although the response was protracted following 
moderate thrombotic stimulation. Thrombosis induced changes in haemodynamic 
performance were sensitive to vasomodulation and were potentiated by both NOS 
inhibition and in eNOS-/- mice. 
In conclusion, endogenous NO and exogenously applied NO donors exert an 
antithrombotic effect in vivo through a direct suppression of platelet aggregation. In 
contrast, eNOS exerts a powerful antithrombotic effect upon the vascular components of 
thrombosis but has a more subtle effect on the duration of thrombotic responses that are 
platelet mediated. Our data demonstrate the differential roles of eNOS and general NO 
bioavailability in regulating vascular and platelet activity during thrombosis.
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Introduction 
Arterial thrombotic diseases such as myocardial infarction are driven by inappropriate 
activation of platelets but additionally include vascular elements, such as arterial 
dysfunction, which can contribute to both the onset and severity of the condition (1, 2). 
Similarly, animal models of thrombosis have both platelet and vascular components (3). 
The contribution of each component to the measured thrombotic response has generally 
not been defined (4) and is likely to vary between models. Thus, the functional 
mechanisms through which nitric oxide (NO), which modifies both platelet and vascular 
function, regulates thrombotic responses are unclear.   
 
NO is a labile signalling molecule that relaxes vascular smooth muscle and hence 
regulates vascular tone (5). Additionally, NO negatively regulates platelet aggregation 
and adhesion (6, 7) and inhibits platelet aggregation in vivo (8). NO therefore has 
multiple antithrombotic properties (9). Although the vascular and platelet modifying 
effects of NO in vitro are well documented, the roles of NO and the various NOS 
enzymes in regulating the platelet and vascular components of thrombosis in vivo are 
poorly understood. This lack of understanding is largely due to the absence of 
experimental models in which the contributions of the vascular and platelet components 
of the thrombotic response are defined.  
 
We have previously used rabbit (8) and mouse (10) models of platelet 
thromboembolism to demonstrate that platelet aggregation in vivo is critically regulated 
by endogenous NO but that loss of enodothelial nitric oxide synthase (eNOS) does not 
potentiate the platelet aggregation response due to compensatory mechanisms that have 
not been fully defined or redundancy between eNOS and other negative regulators of 
Page 4 of 29Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 5 
platelet function (10). A lack of thrombotic phenotype in eNOS-/- mice has been 
reported by a number of groups (11, 12), whereas others contradict these reports by 
describing modified thrombotic responses (13-15). We hypothesised that eNOS exerts a 
limited or negligible anti-platelet effect but modifies the vascular elements of 
thrombosis due to its vasoactive properties (16, 17). Such differential effects of eNOS 
would explain apparently conflicting data concerning the role of this enzyme in 
regulating thrombotic events and further characterise its functional role in the 
cardiovascular system. In the current paper we have addressed this hypothesis using an 
in vivo model of platelet thromboembolism in which parameters are defined that are 
platelet driven but contrast in their dependence on vessel tone.
Page 5 of 29 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 6 
Methods 
Mice 
eNOS knock-out mice (NOS-3-/-, Strain: 0026847) were purchased from Jackson 
Laboratory, ME, USA along with control C57Bl/6J control mice. All animal procedures 
were conducted under our Home Office Project License PPL 70/6358, approved by the 
Ethical Review Panel at Imperial College London and refined in association with the 
National Centre for the Replacement, Refinement and Reduction of Animals in 
Research (NC3Rs) (18). 
 
Materials 
All reagents were purchased from Sigma (Dorset, UK) with the exception of 111Indium 
Oxine (GE Healthcare, Bucks, UK) and collagen (Nycomed Pharma, Germany). All 
drugs were dissolved in saline, apart from collagen which was dissolved in the 
manufacturers’ buffering solution, and were administered as an intravenous bolus 
injection or infusion as described. Drug and molecular target nomenclature in this paper 
conforms to the British Journal of Pharmacology’s Guide to Receptors and Channels 
(19). 
 
Blood collection and platelet labelling 
Blood was collected from terminally anaesthetised (10 ml kg-1 urethane (25%) i.p.) 
donor mice by cardiac puncture, platelets were isolated by centrifugation and 
radiolabelled with 1.8 MBq 111Indium Oxine as previously described (18, 20). 
Radiolabelled platelets were resuspended in 200 µl Ca2+-free Tyrode’s solution per 
mouse and infused into anaesthetised recipient mice via a femoral vein. Circulating 
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platelets were allowed to equilibrate for 15 min. Platelet agonists and drugs were 
administered via an exposed femoral vein. 
 
In vivo platelet aggregation 
Platelet responses were measured as increases in platelet-associated counts in the 
pulmonary vascular bed following intravenous injection of collagen. Data was collected 
via a 1cm SPEAR (Single Point Extended Area Radiation) detector (eV Products, PA, 
US) fixed over the pulmonary vascular bed and recorded on a UCS-20 spectrometer 
(Spectrum Techniques, TN, US) using custom made software (Mumed Systems, 
London, UK). We have previously shown that increases in radioactive counts in this 
model represent the trapping of platelet aggregates formed in the systemic circulation in 
the pulmonary vasculature (18). 
 
Haemodynamic assessment 
Blood pressure and cardiac contractility were measured by surgically exposing and 
cannulating the right common carotid artery of anaesthetised (10 ml kg-1 urethane (25%) 
i.p.) mice with a 1.4 Fr pressure catheter (Millar, Tx, US). The catheter was advanced to 
the aortic arch to measure aortic pressure and then to the left ventricle to measure 
cardiac contractility (dP/dtmax) and left ventricular pressure (LVP) as previously 
described (18, 21). These parameters were continuously measured before and following 
induction of thromboembolism by intravenous injection of collagen. 
 
Page 7 of 29 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 8 
Experimental protocol 
The experimental protocols were identical for the platelet aggregation and 
haemodynamic experiments. Each preparation was allowed to stabilise for 15 min 
before the administration of experimental or control compounds.  Drugs were 
administered intravenously 10 min (5 min for SNP) before injection of collagen and the 
response recorded for 10 min.  
 
Analysis of results 
Stable baseline values were recorded 1 min before the addition of the drug or vehicle.  
All results are expressed as percentage changes from baseline values.  Changes in mean 
radioactive counts or haemodynamic parameters caused by the test drug were compared 
with time-matched vehicle controls using one-way analysis of variance with Benferroni 
post-analysis.  All values are expressed as the mean ± s.e. mean; differences in the mean 
were interpreted as significant when p< 0.05. 
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Results 
Thrombotic and haemodynamic response to collagen 
Collagen induced thromboembolism in vivo that was characterised by a rapid increase in 
radioactive counts in the pulmonary detection probe representing trapping of platelet 
aggregates in the pulmonary vascular bed as previously described (18). Platelet 
responses peaked and returned slowly to baseline as platelets disaggregated. Collagen 
also impaired haemodynamic function measurable as a transient fall in cardiac 
contractility (dP/dtmax) and left ventricular pressure (LVP) due to occlusion of 
pulmonary vessels and subsequent impairment of cardiac haemodynamic function (18). 
Typical traces showing the time course of the platelet and haemodynamic response to 
75 µg kg-1 collagen are shown in Fig 1 and demonstrate that the changes in both platelet 
and haemodynamic parameters occur over a similar time frame.   
 We were able to define dose-dependent changes in platelet aggregation measured as the 
mean maximal % increase in counts at collagen doses of 25-100 µg kg-1 (Fig 2A). These 
doses of collagen also produced dose-dependent concomitant changes in dP/dtmax and 
LVP during haemodynamic assessment as previously reported (18).  
 
Effect of NOS inhibition and vasomodulation on blood pressure 
Administration of the NOS inhibitors L-NAME (Nω-Nitro-L-arginine methyl ester 
hydrochloride, 50 mg kg-1) or ADMA (asym-Dimethylarginine, 50 mg kg-1) 
significantly elevated aortic pressure compared with saline, D-NAME (NG-Nitro-D-
arginine methyl ester hydrochloride) or SDMA (sym-Dimethylarginine) controls (Fig 
3A).  To distinguish the effects of vasoconstriction from platelet mediated effects, we 
established concentrations of the α1-adrenergic agonist and vasoconstrictor 
phenylephrine that produced similar increases in aortic pressure to those observed with 
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L-NAME. Phenylephrine (80 µg kg-1 min-1 for 5 min) produced a similar change in the 
aortic pressure profile as 50 mg-1 kg-1 L-NAME (Fig 3B) such that the mean increases 
in aortic pressure were not different following administration of these two agents (Fig 
3A). The NO donor SNP (sodium nitroprusside, 10 µg kg-1) reduced blood pressure and 
we established that the dihydropyridine calcium-channel antagonist and hypotensive, 
nicardipine, reduced pressure with a similar profile to SNP at 100 µg kg-1 (Fig 3C) such 
that the peak changes in blood pressure obtained with these agents were not different 
(Fig 3A). We also confirmed that, under our experimental conditions, aortic pressure 
was significantly elevated in eNOS-/- mice compared with wild-type controls as 
previously reported (22), data not shown. 
 
Effect of NO and eNOS on platelet aggregation in vivo 
The NOS inhibitors L-NAME (50 mg kg-1) and ADMA (50 mg kg-1) significantly 
potentiated collagen induced platelet aggregation and delayed the return to baseline 
compared to D-NAME and SDMA controls respectively (Fig 4A-B). In contrast, 
phenylephrine, at doses shown to elevate aortic pressure to a similar extent as NOS 
inhibition, had no effect on collagen induced aggregation. In addition, continuous 
infusion of phenylephrine throughout the recording period failed to enhance the 
response to collagen (Fig 4A-B). 
The NO donor, SNP, significantly reduced collagen induced aggregation whereas 
nicardipine, at concentrations producing a comparable reduction in aortic pressure, had 
no effect (Fig 4A-B). 
To assess the role of eNOS in a thrombotic model shown to be driven by platelet 
aggregation but independent of changes in vascular tone, we carried out dose-responses 
to collagen in eNOS-/- and wild-type mice. Collagen (12-75 µg kg-1 i.v.) induced dose-
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dependent platelet aggregation responses in vivo in eNOS-/- and WT mice (Fig 4C-D). 
In contrast to experiments with NOS inhibitors, the amplitude of response (measured as 
maximal increase in counts) was not significantly different between eNOS-/- and WT 
controls at any of the doses tested (Fig 4D). The total response (measured as AUC), 
although not different at low levels of collagen (12 – 25 µg kg-1), was significantly 
elevated in eNOS-/- mice at higher collagen doses (50-75 µg kg-1, Fig 4F) due to a 
protracted return to baseline at these concentrations (Fig 4C-D).  
 
Effect of NO and eNOS on haemodynamic responses in vivo. 
Having established that the NOS inhibitors L-NAME and ADMA enhanced platelet 
aggregation responses in vivo, we went on to look at their effect on the cardiac 
haemodynamic changes elicited by collagen induced thromboembolism. Both L-NAME 
and ADMA significantly enhanced the fall in dP/dtmax and LVP following injection of 
collagen (Fig 5A-B). In contrast to platelet aggregation responses, which were not 
modified by phenylephrine (Fig 4A-B), there was a significant potentiation of the fall in 
dP/dtmax and LVP during collagen induced thromboembolism in the presence of 
phenylephrine compared with saline controls (Fig 5A-B). Similarly to platelet 
responses, SNP significantly reduced the collagen induced haemodynamic response but 
in contrast to the platelet response, which was not modified by nicardipine (Fig 4A-B), 
this agent significantly reduced the fall in dP/dtmax and LVP following injection of 
collagen (Fig 5A-B). 
In order to assess the role of eNOS in a model shown to be driven by platelet 
aggregation but influenced by changes in vascular tone, we carried out experiments in 
eNOS-/- mice. The fall in both dP/dtmax and LVP following collagen (50 µg kg-1) were 
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significantly and dramatically enhanced in eNOS-/- mice compared to wild-type controls 
(Fig 5C-D). 
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Discussion 
The animal model employed in this paper was developed to allow platelet aggregation 
responses to be assessed in vivo and thus investigate the regulation of platelet function 
and thrombus formation by mediators derived from tissues external to the platelet such 
as the vascular endothelium (18). Collagen induced dose-dependent platelet aggregation 
measurable as the trapping of radiolabelled platelet aggregates in the mouse pulmonary 
vasculature. It was unclear whether such responses were driven purely by the magnitude 
of the platelet response or whether changes in vascular tone could exert an effect. Thus, 
although we had previously reported an increase in platelet aggregation in this model 
following NOS inhibition (10), it was unclear whether this observation was entirely 
platelet mediated or was partially influenced by vascular changes. We therefore 
conducted a series of experiments to determine whether changes in blood pressure could 
affect the platelet response in our model. We found that vasoconstriction with 
phenylephrine and vasodilatation with nicardipine induced similar changes in blood 
pressure to those observed with NOS inhibitors and an NO donor respectively but had 
no effect on platelet aggregation. We therefore conclude that the observed ability of 
NOS inhibitors to enhance platelet aggregation is mediated through a direct effect on 
platelets such that endogenous NO exerts an antithrombotic effect by acting directly on 
platelets to negatively regulate their functional response. Similarly, NO donors are able 
to inhibit platelet aggregation in vivo through a direct action on platelets. 
We also observed that platelet thromboembolic responses were accompanied by 
concomitant changes in cardiac haemodynamic performance. Occlusion of pulmonary 
vessels by platelet aggregates leads to overload of the right ventricle. Subsequent 
dilation and hypokinesis of the right ventricle reduces left ventricular pre-load and 
impairs left ventricular contractile function leading to a fall in cardiac output (23). The 
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haemodynamic impact of pulmonary vessel occlusion during collagen induced 
thromboembolism was therefore assessed in the current study as reductions in left 
ventricular dP/dt max and LVP. Haemodynamic changes due to pulmonary vessel 
occlusion, for example during pulmonary embolism in humans, are strongly influenced 
by vessel tone (24, 25).  We therefore hypothesised that the observed changes in dP/dt 
max and LVP, in contrast to platelet responses, would also be influenced by vessel tone. 
We confirmed this by showing increases and decreases in dP/dt max and LVP in the 
presence of phenylephrine and nicardipine respectively. Thus, we were able to define 
distinct parameters in our model (platelet aggregation and cardiac haemodynamic 
changes), both of which were dose-dependently determined by platelet aggregation but 
which contrasted in their sensitivity to changes in blood pressure. When we investigated 
the consequences of pharmacological NOS inhibition upon cardiac haemodynamic 
performance, we observed a potentiation of the response confirming the ability of 
endogenous NO to modify a multifaceted thrombotic response.  
Although inhibition of NOS with inhibitors without isoform specificity was shown to 
enhance both the magnitude and duration of the platelet aggregation response, a 
different effect was observed in eNOS-/- mice. We have previously reported a similar 
level of platelet aggregation in vivo in eNOS-/- and WT mice (10) and this was 
confirmed here for a range of collagen concentrations indicating that although 
endogenous NO represses platelet aggregation in vivo leading to responses of a smaller 
magnitude, this effect is not mediated through eNOS. We also assessed the full time-
course of the platelet response in eNOS-/- and WT mice and found that during mild 
stimulation, there was no difference in the platelet response. This contrasts with data 
with NOS inhibitors in previous studies, where threshold platelet aggregation was 
enhanced by non-selective NOS inhibitors (8, 10). At higher concentrations of collagen, 
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however, we found that although the magnitude of the response was not modified, there 
was an increase in the duration of the response (measured as a significantly increased 
AUC) demonstrating that eNOS plays a role in the resolution of the platelet thrombus 
during moderate to strong thrombotic stimulation. 
We also demonstrated that the magnitude and duration of the haemodynamic response 
to thrombotic stimulation were significantly and dramatically enhanced in eNOS-/- mice. 
These data demonstrate that the thrombotic phenotype of eNOS-/- mice is highly 
dependent upon the sensitivity of the assessed thrombotic parameter to changes in 
vessel tone. In models and diseases with a vascular component, loss of eNOS induces a 
powerful thrombotic effect. In contrast, the effect of eNOS upon platelet driven 
processes is more subtle and relates to the duration rather than the magnitude of the 
response. 
Our data provide an explanation for apparently conflicting data concerning the role of 
eNOS in different experimental models of thrombosis. eNOS plays an important role in 
determining the duration and hence severity of moderate thrombotic stimulation that is 
primarily platelet mediated. Thus, the role of eNOS may not be apparent in models of 
mild thrombosis or in those in which the dynamic progression of the thrombotic event is 
not monitored. In contrast, models with a vascular element are likely to consistently 
reveal a powerful antithrombotic effect of eNOS that is mediated through the vasoactive 
properties of this enzyme. 
 
Our data clarify apparently contradictory data from animal models by demonstrating the 
differential roles of NO derived from eNOS and general NO bioavailability in 
regulating vascular and platelet activity during thrombotic responses. We demonstrate 
that despite the failure of many experimental models of thrombosis to detect a 
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thrombotic phenotype in the absence of eNOS, this enzyme is likely to play a role in 
determining the severity of platelet driven thrombotic events. eNOS is therefore a 
potential therapeutic target in the treatment of both platelet driven and vascular diseases. 
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Figure Legends 
Figure 1 
Time course of the platelet and haemodynamic responses during collagen induced 
platelet thromboembolism. The real-time radiolabelled response to collagen is shown 
as % change in counts against time and shows a rapid increase in counts as platelets 
aggregate in the pulmonary region followed by a slower resolution phase (top panel). 
The middle panel shows a real-time recording of ventricular pressure from a catheter 
situated in the left ventricle of an anaesthetised mouse plotted as pressure (mmHg) 
against time and shows a fall in systolic left ventricular pressure (LVP) upon injection 
of collagen and a slower return to baseline. The lower panel shows a real time recording 
of derived pressures (dP/dt) and shows and changes in dP/dtmax (contractile function) 
and dP/dtmin (speed of relaxation) during collagen injection. All traces are representative 
of n=5. 
 
Figure 2 
Dose-dependent platelet aggregation and haemodynamic responses in vivo. Dose-
response following injection of collagen (25 – 100 µg kg-1 i.v., n=6-7) plotted as time-
course of % change in counts at each collagen dose (upper panel) and maximal % 
increase in platelet-associated counts against collagen concentration (lower panel). The 
graphs show increased platelet aggregation in response to increasing doses of collagen. 
Data are presented as mean ± S.E.M of maximal % change from stable baselines, n=5-7, 
**p<0.01, ***p<0.001. 
 
Figure 3 
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Effect of modified NO bioavailability and vascular tone on basal blood pressure. 
(A) Effect of NOS inhibitors L-NAME and ADMA (50 mg kg-1),  and inactive forms of 
these compounds (D-NAME and SDMA) at equimolar doses, phenylephrine (80 µg kg-1 
min-1), the NO donor SNP (10 µg kg-1) and nicardipine (100 µg kg-1) on systolic arterial 
pressure (SP max). L-NAME and phenylephrine enhanced arterial pressure to a similar 
extent and ADMA also increased blood pressure whereas saline, D-NAME and SDMA 
had no effect. SNP and nicardipine reduced arterial pressure to a similar extent. Data are 
presented as mean maximal change in systolic arterial blood pressure (SP max % 
response) ± S.E.M., n=6-8. (B) Profile in real-time of response to L-NAME (50 mg kg-
1
, broken line) and phenylephrine (80 µg kg-1 x 5 mins, solid line) and (C) SNP (10 µg 
kg-1, solid line) and nicardipine (100 µg kg-1, broken line) showing similar response 
profile of the agents in each response. Data are presented as mean ± S.E.M. % change 
relative to stable baseline (%SP) against time, n=8, **p<0.01. 
 
Figure 4 
Effect of modified NO bioavailabilty and vascular tone on collagen induced platelet 
aggregation in vivo. (A) Mice were pre-treated with NOS inhibitors L-NAME (50 mg 
kg-1) or ADMA (50 mg kg-1) or the inactive forms of these compounds (D-NAME and 
SDMA) at equimolar doses. Alternatively mice were treated with the NO donor SNP 
(10 µg kg-1), the hypertensive phenylephrine (80 µg kg-1 min-1) or the hypotensive 
nicardipine (100 µg kg-1). Platelet aggregation was then induced with collagen (50 µg 
kg-1 i.v.) and the mean maximal response recorded as maximal increase in platelet-
associated counts (Max % Response). NOS inhibitors potentiated the response to 
collagen compared to saline pre-treated controls whereas D-NAME, SDMA and 
phenylephrine had no effect. SNP significantly reduced the platelet response to collagen 
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whereas nicardipine had no effect, n=5-7. (B) Real time traces showing the full time-
course of the mean platelet response to collagen in the presence of the agents outlined 
above (broken lines) and control responses (solid lines), n=5. (C-D) Full time-course of 
the mean platelet response to collagen (12-75 µg kg-1) in wild-type (WT, (C)) and 
eNOS-/- (D) mice, n=5. (E-F) Mean platelet response to collagen (12-75 µg kg-1) in WT 
and eNOS-/- mice expressed as (E) maximal response and (F) trapezoidal area under 
curve (AUC). Data are shown as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5 
Effect of modified NO bioavailabilty and vascular tone on collagen induced 
haemodynamic changes in vivo. (A) Mice were pre-treated with NOS inhibitors L-
NAME (50 mg kg-1) or ADMA (50 mg kg-1) or the inactive forms of these compounds 
(D-NAME and SDMA) at equimolar doses. Alternatively mice were treated with the 
NO donor SNP (10 µg kg-1), the hypertensive phenylephrine (80 µg kg-1) or the 
hypotensive nicardipine (100 µg kg-1). Platelet aggregation was then induced with 
collagen (50 µg kg-1 i.v.) and the accompanying changes in the haemodynamic 
parameters dP/dtmax and systolic left ventricular pressure (LVP) recorded as maximal % 
changes. NOS inhibitors and phenylephrine potentiated the response to collagen 
compared to saline pre-treated controls whereas D-NAME and SDMA had no effect. 
SNP and nicardipine significantly reduced the haemodynamic response to collagen. 
Data are shown as mean ± S.E.M., n=4-7. (B) Typical traces of n=4-7 showing the full 
time-course of the haemodynamic response (as blood pressure (BP) and dP/dt) to 
collagen in the presence of the agents outlined above, (C) full time-course of the 
haemodynamic response (as blood pressure (BP) and dP/dt) to collagen in wild-type and 
eNOS-/- mice showing typical responses of n=6-7 and (D) mean maximal % 
Page 22 of 29Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 23 
haemodynamic response (dP/dtmax and systolic left ventricular pressure (LVP)) to 
collagen in WT and eNOS-/- mice, n=6-7. *p<0.05, **p<0.01, ***p<0.001. 
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Time course of the platelet and haemodynamic responses during collagen induced platelet 
thromboembolism. The real-time radiolabelled response to collagen is shown as % change in counts 
against time and shows a rapid increase in counts as platelets aggregate in the pulmonary region 
followed by a slower resolution phase (top panel). The middle panel shows a real-time recording of 
ventricular pressure from a catheter situated in the left ventricle of an anaesthetised mouse plotted 
as pressure (mmHg) against time and shows a fall in systolic left ventricular pressure (LVP) upon 
injection of collagen and a slower return to baseline. The lower panel shows a real time recording of 
derived pressures (dP/dt) and shows and changes in dP/dtmax (contractile function) and dP/dtmin 
(speed of relaxation) during collagen injection. All traces are representative of n=5.  
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Dose-dependent platelet aggregation and haemodynamic responses in vivo. Dose-response 
following injection of collagen (25 – 100 µg kg-1 i.v., n=6-7) plotted as time-course of % change in 
counts at each collagen dose (upper panel) and maximal % increase in platelet-associated counts 
against collagen concentration (lower panel). The graphs show increased platelet aggregation in 
response to increasing doses of collagen. Data are presented as mean ± S.E.M of maximal % 
change from stable baselines, n=5-7, **p<0.01, ***p<0.001.  
190x254mm (96 x 96 DPI)  
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Effect of modified NO bioavailability and vascular tone on basal blood pressure. (A) Effect of NOS 
inhibitors L-NAME and ADMA (50 mg kg-1),  and inactive forms of these compounds (D-NAME and 
SDMA) at equimolar doses, phenylephrine (80 µg kg-1 min-1), the NO donor SNP (10 µg kg-1) and 
nicardipine (100 µg kg-1) on systolic arterial pressure (SP max). L-NAME and phenylephrine 
enhanced arterial pressure to a similar extent and ADMA also increased blood pressure whereas 
saline, D-NAME and SDMA had no effect. SNP and nicardipine reduced arterial pressure to a similar 
extent. Data are presented as mean maximal change in systolic arterial blood pressure (SP max % 
response) ± S.E.M., n=6-8. (B) Profile in real-time of response to L-NAME (50 mg kg-1, broken 
line) and phenylephrine (80 µg kg-1 x 5 mins, solid line) and (C) SNP (10 µg kg-1, solid line) and 
nicardipine (100 µg kg-1, broken line) showing similar response profile of the agents in each 
response. Data are presented as mean ± S.E.M. % change relative to stable baseline (%ρSP) 
against time, n=8, **p<0.01.  
254x190mm (96 x 96 DPI)  
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Effect of modified NO bioavailabilty and vascular tone on collagen induced platelet aggregation in 
vivo. (A) Mice were pre-treated with NOS inhibitors L-NAME (50 mg kg-1) or ADMA (50 mg kg-1) or 
the inactive forms of these compounds (D-NAME and SDMA) at equimolar doses. Alternatively mice 
were treated with the NO donor SNP (10 µg kg-1), the hypertensive phenylephrine (80 µg kg-1 min-
1) or the hypotensive nicardipine (100 µg kg-1). Platelet aggregation was then induced with 
collagen (50 µg kg-1 i.v.) and the mean maximal response recorded as maximal increase in 
platelet-associated counts (Max % Response). NOS inhibitors potentiated the response to collagen 
compared to saline pre-treated controls whereas D-NAME, SDMA and phenylephrine had no effect. 
SNP significantly reduced the platelet response to collagen whereas nicardipine had no effect, n=5-
7. (B) Real time traces showing the full time-course of the mean platelet response to collagen in the 
presence of the agents outlined above (broken lines) and control responses (solid lines), n=5. (C-D) 
Full time-course of the mean platelet response to collagen (12-75 µg kg-1) in wild-type (WT, (C)) 
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and eNOS-/- (D) mice, n=5. (E-F) Mean platelet response to collagen (12-75 µg kg-1) in WT and 
eNOS-/- mice expressed as (E) maximal response and (F) trapezoidal area under curve (AUC). Data 
are shown as mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001.  
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Effect of modified NO bioavailabilty and vascular tone on collagen induced haemodynamic changes 
in vivo. (A) Mice were pre-treated with NOS inhibitors L-NAME (50 mg kg-1) or ADMA (50 mg kg-1) 
or the inactive forms of these compounds (D-NAME and SDMA) at equimolar doses. Alternatively 
mice were treated with the NO donor SNP (10 µg kg-1), the hypertensive phenylephrine (80 µg kg-
1) or the hypotensive nicardipine (100 µg kg-1). Platelet aggregation was then induced with 
collagen (50 µg kg-1 i.v.) and the accompanying changes in the haemodynamic parameters 
dP/dtmax and systolic left ventricular pressure (LVP) recorded as maximal % changes. NOS 
inhibitors and phenylephrine potentiated the response to collagen compared to saline pre-treated 
controls whereas D-NAME and SDMA had no effect. SNP and nicardipine significantly reduced the 
haemodynamic response to collagen. Data are shown as mean ± S.E.M., n=4-7. (B) Typical traces 
of n=4-7 showing the full time-course of the haemodynamic response (as blood pressure (BP) and 
dP/dt) to collagen in the presence of the agents outlined above, (C) full time-course of the 
haemodynamic response (as blood pressure (BP) and dP/dt) to collagen in wild-type and eNOS-/- 
mice showing typical responses of n=6-7 and (D) mean maximal % haemodynamic response 
(dP/dtmax and systolic left ventricular pressure (LVP)) to collagen in WT and eNOS-/- mice, n=6-7. 
*p<0.05, **p<0.01, ***p<0.001.  
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What is known on this topic What this paper adds 
Nitric oxide regulates platelet and 
vascular function 
Nitric oxide exerts a direct anti-
thrombotic effect on platelets in vivo 
Thrombosis is driven by platelet and 
vascular dysfunction 
eNOS modifies the vascular component 
of thrombotic responses 
The role of eNOS in thrombosis is 
unclear 
eNOS potentiates the duration of 
moderate platelet driven thrombotic 
events 
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